Olaratumab + Doxorubicin for Metastatic Soft-Tissue Sarcoma
1 Pogledi
• 07/18/23
0
0
Ugraditi
administrator
Pretplatnici
William D. Tap, MD; Richard F. Riedel, MD; Victor M. Villalobos, MD, PhD; and Kristen N. Ganjoo, MD, comment on the overall survival benefit seen in the phase II study of doxorubicin and olaratumab, the phase III ANNOUNCE trial, and patient selection for this regimen and data for other regimens.
Prikaži više
Komentari na Facebooku
SORT BY-
Najbolji komentari
-
Najnoviji komentari